You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Merck
Baxter
Mallinckrodt

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

LUMIFY Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Lumify patents expire, and what generic alternatives are available?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

US ANDA Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28th, 2003.

  Start Trial

Summary for LUMIFY
International Patents:37
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3
Drug Prices: Drug price information for LUMIFY
DailyMed Link:LUMIFY at DailyMed
Drug patent expirations by year for LUMIFY
Drug Prices for LUMIFY

See drug prices for LUMIFY

Recent Clinical Trials for LUMIFY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tulane UniversityPhase 4
Ocuphire Pharma, Inc.Phase 2
Wendy LeePhase 4

See all LUMIFY clinical trials

US Patents and Regulatory Information for LUMIFY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LUMIFY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1631293 2014C/042 Belgium   Start Trial PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293 2014/041 Ireland   Start Trial PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293 92462 Luxembourg   Start Trial PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.